NovoCure Limited

NasdaqGS NVCR

NovoCure Limited EBITDA Margin for the year ending December 31, 2023: -34.53%

NovoCure Limited EBITDA Margin is -34.53% for the year ending December 31, 2023, a -194.26% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

NovoCure Limited EBITDA Margin for the year ending December 31, 2022 was -11.73%, a -63.56% change year over year.
NovoCure Limited EBITDA Margin for the year ending December 31, 2021 was -7.17%, a -178.29% change year over year.
NovoCure Limited EBITDA Margin for the year ending December 31, 2020 was 9.16%, a 126.52% change year over year.
NovoCure Limited EBITDA Margin for the year ending December 31, 2019 was 4.05%, a 142.80% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqGS: NVCR

NovoCure Limited

CEO	Ms. Ashley Cordova
IPO Date	Oct. 1, 2015
Location	Jersey
Headquarters	No. 4 The Forum
Employees	1,453
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Composite Materials Eyewear Medical Instruments Pharmaceuticals Robotics

Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Key trends

Past 5 years